non-small cell lung cancer
Conditions
Interventions
Gold Standard:Tissue next genome sequencing detection
to 
of 
tumor 
DNA.
Biomarker: 
Sponsors
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
No minimum to 100 Years
Inclusion criteria
Inclusion criteria: (1) Clinically diagnosed patients with stage III and IV non-small cell lung cancer; (2) must have or can be obtained tissue samples of clinical routine genes (such as EGFR, ALK, ROS1, etc.) test results; (3) Patients with tumor tissue samples and blood samples can be taken at the same time; (4) Newly diagnosed and relapsed patients who had not been discharged within 6 months and treated with chemotherapy; (5) There was no clear evidence of other systemic malignancies when all cases were enrolled; (6) Complete records of clinical observations, imaging examinations, laboratory examinations; (7) Fixed at room temperature. Bronchoscopic biopsy specimens should be fixed within 6-24 hours; surgical specimens should be fixed within 12-48 hours; (8) Paraffin-embedded tumor samples and blood samples should be kept for less than 1 year.
Exclusion criteria
Exclusion criteria: (1) Subjects eventually diagnosed as other diseases, including pleural disease, mediastinal disease, chest wall tumors, etc.; (2) Subjects gave up surgery and related examinations for various reasons, and ultimately could not obtain pathological or cytological findings; (3) The clinical evaluator could not be completed because the physical condition was not related to the examination, refused to be examined, or was interrupted for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ctDNA; | — |
Countries
China
Contacts
Public ContactLI LIU
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed